ArticleJournal of virology2004
Role of minority populations of human immunodeficiency virus type 1 in the evolution of viral resistance to protease inhibitors.
Article in Journal of virology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 91 citations in OpenAlex.
- No clinically significant drug-resistance mutations in HIV-1 subtype C-infected women after discontinuation of NRTI-based or PI-based HAART for PMTCT in Botswana.Journal of acquired immune deficiency syndromes (1999) · 2013Trial
- Transmitted and Acquired HIV-1 Drug Resistance from a Family: A Case Study.Infection and drug resistance · 2020Article
- Effect of therapy switch on time to second-line antiretroviral treatment failure in HIV-infected patients.PloS one · 2017Article
- Dengue Virus Evolution under a Host-Targeted Antiviral.Journal of virology · 2015Article
- Impact of human immunodeficiency virus type-1 sequence diversity on antiretroviral therapy outcomes.Viruses · 2014Review
- Decreased phenotypic susceptibility to etravirine in patients with predicted genotypic sensitivity.PloS one · 2014Article
- HIV-1 Genetic Variability and Clinical Implications.ISRN microbiology · 2013Article
- Resistance-associated variants in chronic hepatitis C patients treated with protease inhibitors.Current gastroenterology reports · 2012Review
- Emergence of minor drug-resistant HIV-1 variants after triple antiretroviral prophylaxis for prevention of vertical HIV-1 transmission.PloS one · 2012Article
- Article
- Tracking the evolution of multiple in vitro hepatitis C virus replicon variants under protease inhibitor selection pressure by 454 deep sequencing.Journal of virology · 2010Article
- Minority variants of drug-resistant HIV.The Journal of infectious diseases · 2010Review
- Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure.The Journal of infectious diseases · 2010Article
- HIV resistance to raltegravir.European journal of medical research · 2009Review
- RT-SHIV subpopulation dynamics in infected macaques during anti-HIV therapy.Retrovirology · 2009Article
- Transmitted drug resistance in nonsubtype B HIV-1 infection.HIV therapy · 2009Article
- Development of a platelet-activating factor antagonist for HIV-1 associated neurocognitive disorders.Journal of neuroimmunology · 2009Article
- Detection and quantification of minor human immunodeficiency virus type 1 variants harboring K103N and Y181C resistance mutations in subtype A and D isolates by allele-specific real-time PCR.Antimicrobial agents and chemotherapy · 2009Article
- Management of paediatric HIV-1 resistance.Current opinion in infectious diseases · 2009Review
- Comparative analysis of nearly full-length hepatitis C virus quasispecies from patients experiencing viral breakthrough during antiviral therapy: clustered mutations in three functional genes, E2, NS2, and NS5a.Journal of virology · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human immunodeficiency virus type 1 (HIV-1) drug resistance results from the accumulation of mutations in the viral genes targeted by the drugs. These genetic changes, however, are commonly detected and monitored by techniques that only take into account the dominant population of plasma virus. Because HIV-1-infected patients harbor a complex and diverse mixture of virus populations, the mechanisms underlying the emergence and the evolution of resistance are not fully elucidated. Using techniques that allow the quantification of resistance mutations in minority virus species, we have monitored the evolution of resistance in plasma virus populations from patients failing protease inhibitor treatment. Minority populations with distinct resistance genotypes were detected in all patients throughout the evolution of resistance. The emergence of new dominant genotypes followed two possible mechanisms: (i) emergence of a new mutation in a currently dominant genotype and (ii) emergence of a new genotype derived from a minority virus species. In most cases, these population changes were associated with an increase in resistance at the expense of a reduction in replication capacity. Our findings provide a preliminary indication that minority viral species, which evolve independently of the majority virus population, can eventually become dominant populations, thereby serving as a reservoir of diversity and possibly accelerating the development of drug resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.